Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

1.8K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.8K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

177
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
177
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

1.4K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
1.4K
Venous Thrombosis IV: Nursing Management01:30

Venous Thrombosis IV: Nursing Management

128
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
128
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

151
Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
151
Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

364
Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
364

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Environmental relevance of adsorption of doxycycline, enrofloxacin, and sulfamethoxypyridazine before and after the removal of organic matter from soils.

Journal of environmental management·2021
Same author

Sulfadiazine, sulfamethazine and sulfachloropyridazine removal using three different porous materials: Pine bark, "oak ash" and mussel shell.

Environmental research·2021
Same author

Sulfadiazine removal using green zero-valent iron nanoparticles: A low-cost and eco-friendly alternative technology for water remediation.

Environmental research·2020
Same author

Single and simultaneous adsorption of three sulfonamides in agricultural soils: Effects of pH and organic matter content.

The Science of the total environment·2020
Same author

Use of biomass ash to reduce toxicity affecting soil bacterial community growth due to tetracycline antibiotics.

Journal of environmental management·2020
Same author

Adsorption-desorption of doxycycline in agricultural soils: Batch and stirred-flow-chamber experiments.

Environmental research·2020

Related Experiment Video

Updated: Dec 10, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K

[Learning with COVID-19: what about anticoagulation?]

E Álvarez-Rodríguez1, R González González, R Torres-Gárate

  • 1Servicio de Urgencias. Hospital Universitario Severo Ochoa. Leganés, Madrid.. diabetes@portalsemes.org.

Anales Del Sistema Sanitario De Navarra
|September 1, 2020
PubMed
Summary
This summary is machine-generated.

COVID-19 patients on therapeutic anticoagulation, particularly low molecular weight heparin (LMWH), face risks. Two cases of abdominal bleeding highlight the need for more evidence on safe anticoagulation strategies during SARS-CoV-2 infection.

More Related Videos

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Related Experiment Videos

Last Updated: Dec 10, 2025

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
23:33

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation

Published on: February 28, 2012

84.2K
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
04:56

Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients

Published on: August 4, 2023

1.1K
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
11:17

Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood

Published on: October 12, 2012

14.2K

Area of Science:

  • Internal Medicine
  • Cardiology
  • Infectious Diseases

Background:

  • SARS-CoV-2 (COVID-19) infection increases the risk of thromboembolic events.
  • Anticoagulation strategies for COVID-19 patients vary, with some recommending therapeutic doses and others prophylaxis.
  • Existing guidelines suggest switching oral anticoagulants to low molecular weight heparin (LMWH) for previously anticoagulated patients.

Observation:

  • Two COVID-19 patients, previously on acenocoumarol and rivaroxaban, were switched to therapeutic doses of LMWH.
  • Both patients developed significant abdominal bleeding despite not having severe clinical data.
  • Abdominal bleeding is an uncommon complication of anticoagulation.

Findings:

  • The concurrent occurrence of these bleeding events in a short period suggests a potential link between therapeutic LMWH and gastrointestinal bleeding in COVID-19 patients.
  • This challenges the routine recommendation of switching to therapeutic LMWH for certain COVID-19 patients.
  • Current evidence on optimal anticoagulation in SARS-CoV-2 infection remains unclear.

Implications:

  • These cases underscore the potential risks associated with therapeutic anticoagulation in COVID-19, even in non-critically ill patients.
  • Further research is crucial to establish clear guidelines for anticoagulation management in SARS-CoV-2 infection.
  • Clinicians should exercise caution when considering therapeutic anticoagulation and monitor closely for adverse events like bleeding.